PLAT, plasminogen activator, tissue type, 5327

N. diseases: 392; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Therapeutic phenotype CTD_human Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole. 22352330 2012
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Biomarker phenotype CTD_human Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole. 22352330 2012
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 AlteredExpression phenotype LHGDN Suppression of endothelial t-PA expression by prolonged high laminar shear stress. 19116134 2009
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Therapeutic phenotype CTD_human Intracardiac thrombus--a rare complication of the steroid resistant nephrotic syndrome. 19348381 2008
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Biomarker phenotype CTD_human Intracardiac thrombus--a rare complication of the steroid resistant nephrotic syndrome. 19348381 2008
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Biomarker phenotype LHGDN Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. 12544772 2003
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Therapeutic phenotype CTD_human Well characterized atheroprotective mechanisms include inhibition of thrombosis (increased tissue-type plasminogen activator and decreased plasminogen activator inhibitor-1), inhibition of endothelial cell apoptosis, limitation of permeability (uptake of low-density lipoprotein), prevention of white blood cell binding and transmigration (no expression of adhesion molecules such as intercellular adhesion molecule-1 [ICAM-1] and vascular cell adhesion molecule-1 [VCAM-1] and no release of monocyte chemotactic protein-1) and increased bioavailability of nitric oxide (because of increased expression of endothelial nitric oxide synthase and manganese superoxide dismutase). 12677255 2002
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Biomarker phenotype CTD_human Well characterized atheroprotective mechanisms include inhibition of thrombosis (increased tissue-type plasminogen activator and decreased plasminogen activator inhibitor-1), inhibition of endothelial cell apoptosis, limitation of permeability (uptake of low-density lipoprotein), prevention of white blood cell binding and transmigration (no expression of adhesion molecules such as intercellular adhesion molecule-1 [ICAM-1] and vascular cell adhesion molecule-1 [VCAM-1] and no release of monocyte chemotactic protein-1) and increased bioavailability of nitric oxide (because of increased expression of endothelial nitric oxide synthase and manganese superoxide dismutase). 12677255 2002
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Therapeutic phenotype CTD_human A new manifestation and treatment alternative for heparin-induced thrombosis. 2123154 1990
CUI: C0040053
Disease: Thrombosis
Thrombosis
0.320 Biomarker phenotype CTD_human A new manifestation and treatment alternative for heparin-induced thrombosis. 2123154 1990